NCT06649162Recruiting
A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy
A Multi-center, Prospective, Cohort Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy
Source: ClinicalTrials.gov · Last updated 18 Oct 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The purpose of this study is to identify the risk of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes in clinical practice and to evaluate the clinical usefulness of Dapagliflozin/Pioglitazone combination therapy
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 10000 (estimated)
- First submitted
- 17 Oct 2024
- Start date
- 30 Sept 2024
- Primary completion date
- 31 Mar 2027
- Lead sponsor
- Boryung Pharmaceutical Co., Ltd
- NCT number
- NCT06649162
What you commit to
- Study type: Observational
- Planned participants: 10000
- From 30 Sept 2024 to the primary completion date, 31 Mar 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Those who have a history of taking a fixed-dose combination of dapagliflozin/pioglitazone at baseline (visit 1).
Other
- Those who are expected to need insulin prescription during the study period.
Who the study is looking for
- Among patients with type 2 diabetes, those who are scheduled to administer a fixed-dose combination of dapagliflozin/pioglitazone at baseline (visit 1)
- Those who voluntarily signed a written personal information collection and usage agreement after listening to an explanation about the objective and method, etc. of this clinical study.
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Andong Hospital Coordinator of this site? Confirm its status | Andong | South Korea | Recruiting |
| Konkuk University Medical Center Coordinator of this site? Confirm its status | Seoul | South Korea | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.